Targets › SLC22A5
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 4; Cardiovascular, Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. (UniProt, O76082)
Open in Phaseline: the race on SLC22A5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beni-Suef University | L-Carnitine Carnitine palmitoyltransferase substrate; facilitates fatty acid β-oxidation and energy me | SLC22A5 | Phase 4 | Hepatic | Dec 2026 |
| Ain Shams University | L-Carnitine Carnitine supplement - enhances fatty acid oxidation and cellular energy metabolism; promo | SLC22A5 | Phase 2 | Reperfusion Injury, Myocardial; Diabetic Foot Ulcer | Dec 2026 |
Reperfusion Injury, Myocardial (1) Diabetic Foot Ulcer (1) Hepatic (1)
mixed (1), small molecule (1)
Ain Shams University (1) Beni-Suef University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.